Recent

COVID-19: to all Fidia Partners, Customers and Suppliers

The health, well-being and safety of the people we engage with, including you, our customers, partners, and suppliers, as well as all of our employees, continues to be a top priority for Fidia.

Read More

COVID-19: communication to Partners, Customers, Suppliers

Fidia has implemented a series of measures, to minimize any potential risks related with the COVID-19 outbreak, guaranteeing full operations in, from and to the factories, as well as transports of goods and supply of materials.

Read More

Fidia Introduces in the US the 3-injection regimen TRILURON™ (sodium hyaluronate)

Florham Park, N.J., December 2, 2019 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., introduce in the US, TRILURON™ (sodium hyaluronate).

Read More

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness